A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

NCT ID: NCT04861987

Last Updated: 2024-10-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-18
• Study Completion Date: 2024-09-09

Brief Summary

This study is an open label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are candidates for fluoropyrimidine monotherapy.

Conditions

Advanced Cancer; Refractory Cancer; Tumor Gastric

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

PCS6422 + Capecitabine

Fixed dose of PCS6422 combined with various doses of Capecitabine administered in 14 day cycles

Group Type: EXPERIMENTAL

PCS6422 and capecitabine

Intervention Type: DRUG

PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.

Interventions

PCS6422 and capecitabine

PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Has advanced, metastatic or unresectable GI tract tumors that are refractory or intolerant to existing available therapies and for whom the investigator recommends fluoropyrimidine monotherapy.

2. Has measurable disease in accordance with Respond Evaluation Criteria in Solid Tumors (RECIST) guidelines (Version 1.1).

3. Is aged ≥18 years

4. Has not received treatment with intravenous (IV) 5 FU or oral 5 FU analogs in the 4 weeks preceding enrollment

5. Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 at study entry

6. Has adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days before starting study treatment:

1. peripheral ANC of ≥1.5 × 109/L

2. platelet count of ≥75 × 109/L without growth factor/transfusion

3. hemoglobin ≥8.5 g/dL without growth factor/transfusion

4. estimated glomerular filtration rate >50 mL/min

5. total bilirubin <2 × upper limit of normal (ULN); <5 × ULN if patient has liver metastases, biliary tract cancer; or ≤3 × ULN if the patient has Gilbert's disease

6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2.5 × ULN, with liver metastasis <5 × ULN

7. international normalized ratio (INR) <1.5

7. Has a life expectancy of at least 12 weeks

8. Female patients of childbearing potential and male patients with partners capable of reproduction must agree to use an effective contraceptive method from the time of Screening through 60 days after the last dose of capecitabine

9. Females of childbearing potential must have a negative serum β human chorionic gonadotropin pregnancy test result

10. Willingly provides written, informed consent.

11. Has resolution or stabilization of acute toxicity from prior therapy to Grade <2 - except Grade 2 neuropathy

12. If patient has human immune deficiency virus (HIV) infection, it is controlled with undetectable viral load with antiretroviral treatment.

13. If patient has hepatitis C infection and received antiviral treatment, has a negative viral load at Screening

14. If patient has chronic hepatitis B infection and is receiving antiviral treatment, has a negative viral load at Screening.

15. Is willing and able to comply with all protocol required visits and assessments

Exclusion Criteria

1. Is unable to take oral medication or malabsorption syndromes potentially interfering with medication absorption (e.g., short bowel syndrome or chronic, partial bowel obstruction)

2. Has history or presence of clinically significant abnormal 12 lead ECG results, in the investigator's opinion

3. Has current brain metastasis

4. Has prolonged QTc (with Fridericia's correction) of >480 msec in men and women performed at Screening

5. Has a history of prolonged QTc interval, ventricular tachycardia/fibrillation or significant ventricular arrhythmia, or Torsades de Pointes, or a history of ventricular ablation for arrhythmia

6. Has congenital long QT syndrome or a family history of long QT syndrome

7. Has other clinically significant cardiac disease including, but not limited to, uncontrolled angina, myocardial ischemia or infarction within 6 months, congestive heart failure >Class II per the New York Heart Association, or history of myocarditis

8. Has an electrolyte disturbance, such as uncorrected hypokalemia/hyperkalemia, hypomagnesemia, or hypocalcemia. Patients can be enrolled following successful correction of an electrolyte disturbance.

9. Is currently using any drugs included in the prohibited medications list in the protocol (including those that can prolong QTc) that cannot be discontinued

10. Has known hypersensitivity to any of the components of study treatments

11. Has other primary cancer requiring treatment within the last 3 years, except for cervical intraepithelial neoplasia, ductal carcinoma in situ, or completely excised squamous or basal cell carcinoma

12. Is a pregnant or lactating female

13. Had major surgery, open biopsy, or significant traumatic injury within 4 weeks prior to the first dose of study treatment

14. Is receiving or has received any investigational treatment within 4 weeks prior to study entry, or participating in another clinical study

15. Has known DPD deficiency

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Processa Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sian Bigora, Pharm. D

Role: STUDY_DIRECTOR

Processa Pharmaceuticals

Locations

Processa Clinical Site

Omaha, Nebraska, United States

Processa Clinical Site

New Brunswick, New Jersey, United States

Processa Clinical Site

Santa Fe, New Mexico, United States

Processa Clinical Site

New York, New York, United States

Processa Clinical Site

Cleveland, Ohio, United States

Processa Clinical Site

Fairfax, Virginia, United States

Countries

United States

Other Identifiers

PCS6422-GI-01

Identifier Type: -

Identifier Source: org_study_id